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MaOBJECTIVES The aim of this study was to deﬁne age-stratiﬁed, procedure-speciﬁc benchmark radiation dose levels
during interventional catheterization for congenital heart disease.
BACKGROUND There is a paucity of published literature with regard to radiation dose levels during catheterization for
congenital heart disease. Obtaining benchmark radiation data is essential for assessing the impact of quality improvement
initiatives for radiation safety.
METHODS Data were obtained retrospectively from 7 laboratories participating in the Congenital Cardiac Catheteri-
zation Project on Outcomes collaborative. Total air kerma, dose area product, and total ﬂuoroscopy time were obtained
for the following procedures: 1) patent ductus arteriosus closure; 2) atrial septal defect closure; 3) pulmonary valvulo-
plasty; 4) aortic valvuloplasty; 5) treatment of coarctation of aorta; and 6) transcatheter pulmonary valve placement.
RESULTS Between January 2009 and July 2013, 2,713 cases were identiﬁed. Radiation dose benchmarks are presented
including median, 75th percentile, and 95th percentile. Radiation doses varied widely between age groups and procedure
types. Radiation exposure was lowest in patent ductus arteriosus closure and highest in transcatheter pulmonary valve
placement. Total ﬂuoroscopy time was a poor marker of radiation exposure and did not correlate well with total air kerma
and dose area product.
CONCLUSIONS This study presents age-stratiﬁed radiation dose values for 6 common congenital heart interventional
catheterization procedures. Fluoroscopy time alone is not an adequate measure for monitoring radiation exposure.
These values will be used as baseline for measuring the effectiveness of future quality improvement activities by
the Congenital Cardiac Catheterization Project on Outcomes collaborative. (J Am Coll Cardiol Intv 2014;7:1060–9)
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AB BR EV I A T I O N S
AND ACRONYM S
ACC = American College of
Cardiology
ASD = atrial septal defect
CHD = congenital heart disease
C3PO = Congenital Cardiac
Catheterization Project on
Outcomes
DAP = dose area product
Ka,r = total air kerma
PCI = percutaneous coronary
intervention
PDA = patent ductus arteriosus
QI = quality improvement
TPV = transcatheter
pulmonary valve
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1061studies in children and substantial technical advance-
ments in catheterization equipment have led to rela-
tively lower radiation doses (4). However, over the
same period, the complexity and relative number of
interventional transcatheter procedures have
increased (5–8). Although reference levels for radia-
tion exposure have been widely used outside of pedi-
atric cardiology, limited data are available with
regard to radiation exposure in patients with CHD
undergoing catheterization and interventions (9–16).
Obtaining benchmark radiation exposure data for
congenital cardiac catheterization is challenging due
to the wide variation in procedure complexity, which
is affected by underlying pathology as well as the type
and quality of previously obtained imaging. Varying
age, size, equipment speciﬁcations, and performer
skills add to this heterogeneity. Establishing baseline
values is important for assessing the impact of quality
measures being undertaken to minimize exposure as
well as for intra- and interfacility comparisons. The
Quality Metrics Working Group of the American Col-
lege of Cardiology (ACC) has endorsed a dose metric
for CHD catheterizations deﬁned as the proportion
of patients who receive radiation doses higher than
95th percentile of a pre-deﬁned dataset (17). Appli-
cation of this metric has been impeded by a paucity
of published radiation data for congenital cardiac
catheterization procedures.
The goal of the present study was to analyze
radiation exposure for 6 common interventional
procedures using the Congenital Cardiac Catheteri-
zation Project on Outcomes (C3PO) database. The
C3PO collaborative multicenter group was founded in
2006 to better understand case-mix variation and to
develop outcome measures for patients undergoing
catheterization for CHD (18). The collaborative
currently has 15 participating institutions and has
initiated a quality improvement (QI) (C3POQI) project
with the primary aim of reducing radiation exposure.
We aimed to deﬁne initial benchmark radiation
dose values for C3POQI that will be reassessed bian-
nually (Figure 1). With QI initiatives, we expect these
benchmark values to decrease over time. The results
of the present study will allow application of the ACC-
endorsed dose metric and will provide data to assess
improvements in the future.
METHODS
All 15 participating centers in the C3PO collaborative
were invited to contribute radiation dose data for
the following 6 interventions: 1) patent ductus
arteriosus (PDA) closure; 2) atrial septal defect (ASD)
closure; 3) pulmonary valvuloplasty; 4) aorticvalvuloplasty; 5) treatment of coarctation of
the aorta; and 6) transcatheter pulmonary
valve (TPV) placement. Seven of the 15 cen-
ters were able to retrospectively retrieve
total ﬂuoroscopy time and dose area pro-
duct (DAP), and only 5 centers were able
to retrieve total air kerma (Ka,r). Although
most modern equipment is capable of re-
porting delivered dose at the time of the
study, in most instances, the values must be
recorded in a database or patient report at
the time of the study. Unless recorded at the
time of the study, these cannot be retrieved
retrospectively. Centers that were unable to
provide data were those that did not routinely
record or report radiation doses during the
study period. Technical data about the equip-
ment and procedure were obtained and
included the year of purchase of the equipment,
equipment vendor, availability and use of the “store
ﬂuoro” feature (“store ﬂuoro” is a feature/button on
catheterization equipment. Hitting the button stores
a ﬂuoroscopic image that otherwise would have been
discarded by the system. This feature is often ignored
leading to more radiation exposure.), use of digital
subtraction angiography, use of antiscatter grid, and
use of copper ﬁltration.
The cited procedures are typically performed as
isolated cases and were selected to represent a rela-
tively homogeneous case mix. The 5 procedures other
than TPV placement are also captured in the IMPACT
(Improving Pediatric and Adult Congenital Treat-
ments) registry; however, these data have not been
published (19). Procedures performed between
January 2009 and July 2013 were included with 1
exception. The Medtronic Melody transcatheter
pulmonary valve was approved for use in the United
States in January 2010. To account for performer
learning curve, data collection for this lesion
was commenced in January 2011. Approval was
obtained from either institutional review boards or
quality improvement committees of the participating
centers.
Patients were stratiﬁed by age and intervention
type. Five age groups were deﬁned based on previous
publications to facilitate comparisons (younger than
1 year of age, 1 to 4 years of age, 5 to 9 years of age,
10 to 15 years of age, and older than 15 years of age)
(20,21). Although different centers varied with regard
to imaging equipment, radiation doses were calcu-
lated automatically according to standard existing
federal laws. The following variables were analyzed.
1) Total air Ka,r expressed in mGy and estimated as the
sum of radiation doses in anteroposterior and lateral
FIGURE 1 Key Elements of C3POQI Initiative
Proposed elements of Congenital Cardiac Catheterization Project on Outcomes collaborative’s quality improvement project. C3POQI ¼
Congenital Cardiac Catheterization Project on Outcomes Quality Improvement; PDSA ¼ Plan-Do-Study-Act cycle.
Ghelani et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 9 , 2 0 1 4
Radiation During Congenital Catheterization S E P T E M B E R 2 0 1 4 : 1 0 6 0 – 9
1062imaging planes. Ka,r is the radiation dose accumu-
lated at a speciﬁc point in space (the patient entrance
reference point) relative to the ﬂuoroscopic gantry.
It is used as a predictor of the risk of deterministic
effects, such as radiation-induced skin injury (22).
2) DAP expressed in Gy$cm2 is the surface integral of
air kerma and represents the product of radiation
dose and exposed area. It is expressed as a sum of
anteroposterior and lateral DAPs. It is a surrogate
measure of the amount of energy delivered to the
patient and thus a reasonable indicator of the risk of
stochastic effects (23). 3) Total ﬂuoroscopy time
expressed in minutes as a sum of anteroposterior and
lateral ﬂuoroscopy times.
Data were summarized as medians, 75th percentile,
and 95th percentile and their 95% conﬁdence intervals
(24). Stratiﬁed age groups as well as total values are
presented for each of the 6 procedures. Further,
smoothed percentile curves for total DAP and total air
Ka,r versus weight were estimated separately for the 4diagnosis groups (PDA, ASD, pulmonary valvuloplasty,
and aortic valvuloplasty) using quantile regression;
50th, 75th, and 95th percentiles were generated.
RESULTS
Among the 7 centers that contributed data, there
were 15 catheterization laboratories. Catheterization
equipment was installed between 2001 and 2009
and was supplied by 4 different vendors for 8
(Siemens AG, Medical Solutions, Malvern, Pennsyl-
vania), 4 (Phillips Healthcare, Andover, Massachu-
setts), 2 (Toshiba America Medical Systems, Tustin,
California), and 1 (GE Healthcare, Wauwatosa,
Wisconsin) laboratories, respectively. Six of the 7
centers followed a default frame rate for ﬂuoroscopic
(10 frames per second at 1 center, 15 frames per
second at 4 centers, and 30 frames per second at 1
center) and digital acquisition (15 frames per second
at 4 centers, 30 frames per second at 2 centers). All
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1063the centers reported the use of the store ﬂuoro
feature; however, there was a wide range in the pro-
portion of cases in which this was done (10% to 95%).
One center used digital subtraction angiography.
Six of the 7 centers used an antiscatter grid and 5
of the 5 centers that responded used copper ﬁltra-
tion. The total number of operators in the 7 partici-
pating centers for the cases included in the study
was 22. The number of operators per center ranged
from 2 to 5 (median, 2 operators). Operator experi-
ence was gauged by the average number of cathe-
terizations performed by each operator per year and
ranged from 60 to 261 per year (median, 151
procedures).
A total of 2,713 cases were analyzed, and the
number of cases per individual center ranged from
142 to 858 (median, 306 cases). A TPV was placed in
only 2 patients between 1 and 4 years of age and in
8 patients between 5 and 9 years of age. ASD closure
was performed in only 6 patients younger than 1 year
of age. Data for these 3 categories of patients are not
presented due to small sample size. Lesion dis-
tribution of radiation dose variables is presented in
Table 1. Age-based stratiﬁcation is presented in
Tables 2 to 4.
Of the analyzed procedures, TPV placement had
the highest median Ka,r and DAP values at 2,286 mGy
and 230 Gy$cm2, respectively. Median and 75th and
95th percentile curves for PDA, ASD, pulmonary
valvuloplasty, and aortic valvuloplasty are presented
in Figure 2. The lowest radiation doses were noted
in PDA closure and pulmonary valvuloplasty, with a
median Ka,r of 109 mGy and 114 mGy, respectively,
and DAP of 7 Gy$cm2 each.
Total ﬂuoroscopy time was not a good measure of
radiation exposure and correlated poorly with DAP
and Ka,r, as seen in Figure 3. For example (Table 1),
comparing TPV placement with aortic valvuloplasty,
the ﬂuoroscopy time was only double for TPV;
however, the radiation exposure by Ka,r or DAP mea-
sures was w600% higher for TPV placement.TABLE 1 Radiation Doses for 6 Selected Interventional Catheterizatio
Procedure Total No.
Total Air Kerma, mGy
n Median 75th Percentile 95th Percentile
PDA 548 362 109 175 758 5
ASD 731 532 240 549 1,948 7
PS 462 362 114 258 1,053 4
AS 297 238 215 605 1,734 2
CoA 452 360 305 940 3,531 4
TPV 223 200 2,286 3,424 6,041
AS ¼ aortic stenosis; ASD ¼ atrial septal defect; CoA ¼ coarctation of aorta; PDA ¼ patDISCUSSION
This is the ﬁrst multicenter report of procedure-
speciﬁc radiation doses during interventional cathe-
terization for CHD. Benchmark values were generated
from relatively homogeneous, age-stratiﬁed patient
groups from 7 centers participating in the C3POQI
collaborative. With ongoing QI efforts, as has
occurred in other specialties, we anticipate radiation
exposure measures to decline over time (9,10).
Moreover, these benchmarks will provide a guideline
to interventional cardiologists striving to achieve
radiation doses as low as reasonably attainable (16).
We recommend the use of DAP and Ka,r, but not
ﬂuoroscopy time, as measures of radiation exposure
that are readily available and have shown good
correlation with effective radiation dose (mSv) in
patients (25). The present study suggests that
radiation exposure varies widely among procedure
type and age groups. Hence, in contrast to recom-
mendations made by some previous studies, we
recommend following procedure-speciﬁc benchmarks
over a common reference value for all interventional
procedures (1,26).
Limited procedure-speciﬁc reference values are
available in the published literature. Verghese et al.
(12) reported procedure-speciﬁc radiation doses from
a single large center in the United States that also
contributed data to the present study. Al-Haj et al.
(14) reported their experience in Saudi Arabia. In
their series, 41 patients with PDA, with a mean age of
2.4 years, had a DAP of 23.21  10.1 Gy$cm2; and 44
patients who underwent pulmonary valvuloplasty,
with a mean age of 2.9 years, had a DAP of 9.96 
15.1 Gy$cm2. Although it is difﬁcult to make direct
comparisons, age group–independent median values
for PDA and pulmonary valvuloplasty in the present
series are notably lower. In contrast, patients with
coarctation of the aorta in the present study received
much higher DAP than those in the Al-Haj et al. se-
ries (n ¼ 24; mean age, 2.8 years; DAP 11.35  24.3n Procedures
Dose Area Product, Gy$cm2 Total Fluoroscopy Time, min
n Median 75th Percentile 95th Percentile n Median 75th Percentile 95th Percentile
47 7 16 91 544 12 17 32
26 21 62 284 726 18 28 58
61 7 18 158 461 20 32 68
96 14 60 187 296 25 35 66
48 29 103 367 452 22 33 67
223 230 372 825 223 55 75 133
ent ductus arteriosus; PS ¼ pulmonary stenosis; TPV ¼ transcatheter pulmonary valve placement.
TABLE 2 Total Air Kerma (mGy) Stratiﬁed by Procedure Type and Age Group
Procedure
Age, yrs
<1 1–4 5–9 10–15 >15
PDA
No. 96 181 39 27 19
Median 76 (65–90) 96 (90–111) 160 (114–182) 300 (198–628) 949 (643–1,686)
75th percentile 118 (102–135) 140 (126–153) 195 (168–326) 715 (386–1,547) 1,686 (949–3,170)
95th percentile 230 (192–450) 253 (213–365) 392 (290–448) 1,551 (827–1,557) 3,170 (1,750–3,170)
ASD
n 6 157 142 98 129
Median — 120 (101–134) 188 (156–211) 444 (310–550) 630 (550–954)
75th percentile — 220 (180–266) 300 (247–389) 768 (620–900) 1,470 (1,220–1,949)
95th percentile — 528 (400–717) 670 (525–991) 1,738 (1,168–3,078) 3,853 (3,243–5,046)
PS
n 244 44 18 31 25
Median 87 (79–96) 133 (119–153) 244 (100–351) 319 (272–512) 1,781 (778–2,430)
75th percentile 148 (127–174) 208 (147–282) 351 (255–698) 862 (436–1,144) 2,603 (1,789–4,976)
95th percentile 323 (289–417) 365 (282–536) 698 (382–698) 1,456 (1,053–1,710) 4,976 (3,652–9,048)
AS
n 123 20 18 55 22
Median 122 (107–139) 258 (177–405) 170 (137–296) 780 (464–901) 882 (788–1,420)
75th percentile 204 (170–238) 421 (264–979) 296 (182–664) 1,136 (897–1,570) 1,420 (894–4,531)
95th percentile 361 (294–531) 1,377 (462–1,775) 664 (379–664) 2,111 (1,585–2,842) 4,531 (2,216–5,310)
CoA
Median 137 (121–156) 233 (191–307) 444 (289–700) 1,043 (834–1,358) 1,716 (1,436–2,420)
75th percentile 228 (182–265) 373 (256–585) 768 (536–1,376) 1,696 (1,317–2,877) 3,024 (2,420–4,375)
95th percentile 600 (411–857) 826 (562–1,089) 1,546 (920–1,771) 3,604 (2,901–4,442) 7,128 (4,948–8,274)
TPV
n 0 2 8 55 135
Median — — — 1,461 (905–2,151) 2,502 (2,332–3,026)
75th percentile — — — 2,675 (1,837–3,233) 4,050 (3,383–4,656)
95th percentile — — — 4,579 (3,256–6,538) 6,820 (5,367–9,983)
Values in parentheses are 95% conﬁdence interval.
Abbreviations as in Table 1.
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1064Gy$cm2). This is likely explained by a larger number
of older patients undergoing coarctation stenting in
the present series. In a study by Ubeda et al. (21),
DAP values for aortic angioplasty, ASD closure, PDA
occlusion, and pulmonary valvuloplasty were lower
than in the present report. Differences in equipment,
operator techniques, patient age and size, and
complexity of underlying pathology are likely major
contributors to these differences. Sawdy et al. (27)
reported radiation dose assessment for >400
congenital heart procedures in a medium-size pedi-
atric cardiac program and the effect of a protocol for
dose reduction over time. The report includes doses
for ASD and PDA closure, although radiation dose
was not indexed to body surface area, and there was
no grouping by age or patient size. They observed a
signiﬁcant reduction in the median cumulative Ka,r
for both ASD device closure (1,051 mGy vs. 634
mGy vs. 452 mGy vs. 140 mGy, p < 0.001) and PDA
closure (328 mGy vs. 297 mGy vs. 301 mGy vs. 126mGy, p < 0.001) over time. There was signiﬁcant
variability in the doses reported, as the cumulative
Ka,r reported for ASD closure ranged from as high as
15,795 mGy to as low as 49 mGy during the study
period. Similarly for PDA closure, it ranged from as
high as 4,596 mGy to as low as 66 mGy. This study
demonstrates the signiﬁcant variability in radiation
doses in congenital procedures and enhances the
importance of tracking radiation dose versus ﬂuo-
roscopy times. As there was no speciﬁcation of dose
according to patient age and size, it would not seem
possible to compare the doses reported for ASD and
PDA closure with those in the present study. How-
ever, it appears that the values reported by Sawdy
et al. are somewhat higher.
Values obtained in the present study can be
compared with published adult data to put the
numbers in perspective. Using data from 171 facilities
in 30 states in the United States, Miller et al. (28) from
the U.S. Food and Drug Administration have proposed
TABLE 3 Dose Area Product (Gy$cm2) Stratiﬁed by Procedure Type and Age Group
Age, yrs
<1 1–4 5–9 10–15 >15
PDA
n 130 294 60 38 25
Median 5 (4–6) 7 (6–8) 13 (10–15) 33 (17–66) 96 (70–146)
75th percentile 8 (7–10) 12 (10–14) 22 (15–31) 85 (51–146) 151 (96–253)
95th percentile 22 (16–50) 49 (39–65) 48 (33–97) 207 (142–249) 253 (179–268)
ASD
n 6 219 180 127 194
Median — 9 (8–10) 14 (11–16) 39 (31–50) 89 (71–113)
75th percentile — 17 (14–22) 25 (20–32) 67 (58–90) 204 (174–262)
95th percentile — 58 (48–84) 86 (58–129) 182 (137–568) 532 (405–716)
PS
n 303 64 24 35 35
Median 4 (3–4) 10 (8–13) 16 (11–21) 44 (32–79) 198 (117–340)
75th percentile 9 (7–10) 18 (13–28) 23 (18–66) 98 (50–120) 448 (264–829)
95th percentile 25 (18–51) 46 (31–610) 66 (30–72) 156 (108–158) 1,336 (556–6,425)
AS
n 155 27 22 65 27
Median 7 (5–8) 19 (12–33) 21 (13–28) 93 (70–121) 116 (82–173)
75th percentile 11 (10–14) 37 (21–67) 28 (25–57) 137 (121–161) 187 (128–576)
95th percentile 27 (22–52) 144 (53–144) 57 (41–83) 295 (211–553) 1,771 (284–2,172)
CoA
n 202 36 38 79 93
Median 7 (6–9) 20 (14–24) 41 (30–53) 96 (72–123) 200 (162–250)
75th percentile 14 (12–18) 30 (20–53) 65 (47–98) 170 (133–210) 340 (270–571)
95th percentile 45 (36–85) 62 (43–112) 179 (76–449) 303 (231–494) 933 (659–4,981)
TPV
n 0 2 8 59 154
Median — — — 147 (96–176) 288 (251–312)
75th percentile — — — 249 (176–323) 430 (388–496)
95th percentile — — — 540 (331–2,362) 902 (753–1,307)
Values in parentheses are 95% conﬁdence interval.
Abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 9 , 2 0 1 4 Ghelani et al.
S E P T E M B E R 2 0 1 4 : 1 0 6 0 – 9 Radiation During Congenital Catheterization
1065a Ka,r reference level (75th percentile of representa-
tive data) of 1.18 Gy for diagnostic catheterization and
3.12 Gy for percutaneous coronary interventions
(PCIs). In the older than 15 years age subgroup of the
present study with patients closest to adult size, TPV
placement exceeded the PCI reference level (4.05 Gy),
whereas other interventional procedure types were
between the diagnostic and PCI reference levels.
These high doses are important to note given that
many patients with CHD would have had previous
catheterization(s) and may have more procedures in
the future.
Radiation exposure during catheterization for CHD
is an important issue. Children are exposed to a
relatively smaller total dose of radiation due to their
smaller size; hence, the incidence of deterministic
effects such as skin necrosis is low (1,29). However,
longer life expectancy compared with adults under-
going catheterization for coronary artery disease putsthem at a higher risk of long-term stochastic effects
such as malignancy (30,31). The need for multiple
catheterizations and higher tissue sensitivity adds to
this long-term risk in children (2,3,32). International
authorities on radiation safety have estimated that
the risk of stochastic effects such as malignancies is at
least 2 to 3 times higher in children compared
with adults (31,33). Previous single-center studies
have reported success with reduction in radiation
doses with standardized catheterization protocols
(12,27,34,35). A number of recent technical advances
have had a positive impact on radiation doses in the
catheterization laboratory. Most prominent among
these are the introduction of isocentric biplane im-
aging systems, the use of all-digital systems with
ready ability to replay previous acquisitions, the use
of strong copper ﬁltration in x-ray tubes, and the use
of high-efﬁciency ﬂat-panel image detectors (4).
Alternative imaging techniques have successfully
TABLE 4 Total Fluoroscopy Time (min) Stratiﬁed by Procedure Type and Age Group
Age, yrs
<1 1–4 5–9 10–15 >15
PDA
n 129 292 60 38 25
Median 15 (13–16) 10 (10–11) 11 (9–13) 12 (10–15) 24 (18–30)
75th percentile 21 (19–24) 16 (14–17) 15 (13–23) 17 (12–20) 33 (24–49)
95th percentile 33 (28–49) 28 (22–34) 28 (23–33) 36 (19–38) 49 (43–67)
ASD
n 6 222 180 127 191
Median — 18 (16–20) 16 (15–18) 17 (15–19) 20 (18–24)
75th percentile — 27 (23–31) 24 (22–28) 27 (23–36) 31 (29–34)
95th percentile — 64 (51–81) 49 (39–64) 56 (45–83) 55 (47–88)
PS
n 303 64 24 35 35
Median 21 (18–23) 19 (16–23) 13 (9–20) 15 (13–20) 28 (22–36)
75th percentile 35 (30–40) 30 (23–36) 20 (15–63) 22 (18–27) 42 (31–56)
95th percentile 72 (65–77) 64 (37–329) 63 (24–114) 47 (26–62) 61 (49–86)
AS
n 155 26 22 66 27
Median 25 (22–27) 21 (16–33) 22 (18–30) 28 (25–32) 23 (19–39)
75th percentile 34 (31–42) 33 (25–58) 30 (23–52) 36 (32–40) 39 (26–55)
95th percentile 70 (58–90) 58 (48–128) 52 (35–57) 49 (40–270) 55 (49–62)
CoA
n 205 37 38 79 93
Median 21 (19–24) 23 (20–29) 22 (18–29) 20 (18–23) 24 (22–31)
75th percentile 32 (29–39) 35 (28–60) 33 (27–48) 26 (23–35) 36 (33–46)
95th percentile 66 (56–78) 67 (46–69) 55 (38–73) 53 (39–90) 80 (59–723)
TPV
n 0 2 8 59 154
Median — — — 50 (38–61) 55 (49–57)
75th percentile — — — 74 (61–107) 75 (68–89)
95th percentile — — — 146 (114–173) 131 (101–222)
Values in parentheses are 95% conﬁdence interval.
Abbreviations as in Table 1.
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1066been used to decrease radiation exposure during
catheterization for electrophysiology procedures (36).
More recently, an x-ray magnetic resonance fusion
technique has been investigated as a potential method
to reduce radiation exposure for congenital catheteri-
zation (37). For procedures such as ASD closure, the
radiation dose may depend on the relative use of
transesophageal echocardiography and/or intracar-
diac echocardiography compared with cine or ﬂuo-
roscopy. Despite these advances, cardiologists are
obliged to minimize radiation exposure. This is espe-
cially important for patients undergoing prolonged
procedures for complex pathology and those under-
going multiple procedures during their lifetimes.
Some studies have reported DAP values per
kilogram to account for dose variability based on
weight (11,26). The present study was able to esti-
mate weight-based percentile curves for 4 of the 6
analyzed procedures and show a gradual increase inexposure with weight. However, there is a paucity
of pediatric literature with regard to correlation of
radiation doses with anthropometric parameters. In
addition to age, the radiation dose may be affected
by sex, weight, chest shape, chest thickness, angle
of projection, and the presence of pulmonary
pathology (26,38–41). Additionally, for reliable data
on quality and outcomes, standardizing clinical
practice is of utmost importance. As a part of its QI
initiative, the C3PO plans to implement an educa-
tional module for participating centers with an
emphasis on staff education, technique optimization,
equipment standardization, and interval outcome
assessments (Figure 1). Ongoing multicenter efforts,
collaboration with industry, and uniform case and
radiation dose deﬁnitions will be of the utmost
importance to obtain nationally representative data
for future QI initiatives and periodic assessments.
STUDY LIMITATIONS. This study must be viewed in
light of its potential limitations. We report Ka,r,
which represents the cumulative dose for the entire
examination. To best estimate the risk of determin-
istic injury to the patient, one must estimate the
maximal Ka,r among all the skin ports on the
patient’s body through which the different x-ray
projections passed. The second parameter that we
report is the cumulative DAP. Although DAP is a
reasonable estimate of stochastic risk, further as-
sumptions must be made to estimate effective dose
(mSv) (25). The reported parameters were chosen
based on ease of obtaining from multiple centers,
their availability from modern ﬂuoroscopy equip-
ment, and because they are the most commonly
reported measures in published literature. However,
different centers use different equipment and pro-
tocols. In the absence of standardized practice, the
presented percentiles should be viewed as real-world
baselines rather than guideline or reference levels
that a center should aim to achieve. As C3PO evalu-
ates radiation doses prospectively from a larger
number of centers, future data are likely to be more
homogeneous and representative. All 15 centers
participating in the C3POQI were approached, but
only 7 could retrospectively obtain required param-
eters. The collaborative continues to work with
manufacturers to modify equipment so that radiation
dose information is easily accessible. Although
measurement procedures are standardized, there is a
possibility of skewed data based purely on this fact.
Using percentile values for data from 7 different
centers may reduce the chance of such an error. As
some centers in the database performed many more
procedures than others, results of this study may be
FIGURE 2 Weight-Based Percentile Curves for Ka,r and Total Dose Area Product
Weight-based, smoothed 50th, 75th, and 95th percentile curves for total air kerma (Ka,r) (A) and dose area product (B). AS ¼ aortic stenosis;
ASD ¼ atrial septal defect; PDA ¼ patent ductus arteriosus; PS ¼ pulmonary stenosis.
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1067unevenly affected by procedures and practices in
these larger centers. However, center level analysis
was precluded by a relatively small number of cases
per center in individual categories. We reported data
for only 6 speciﬁc procedures that represent afraction of those that take place in the pediatric
catheterization lab. Although we attempted to query
lesions that typically occur in isolation and are
relatively “simple,” there is a possibility of signiﬁ-
cant heterogeneity within each group. For example,
FIGURE 3 Fluoroscopy Time, Dose Area Product, and Ka,r for 5 Types of Procedure
Lack of correlation of ﬂuoroscopy time with dose area product and Ka,r. DAP ¼ dose area
product; CoA ¼ coarctation of aorta; other abbreviations as in Table 2.
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1068aortic coarctation interventions included balloon
angioplasty, primary stenting, secondary stenting,
and stent redilation, which have differing levels of
risk and perhaps a need for additional angiograms
and ﬂuoroscopy time. Similarly, patients with mul-
tiple ASDs requiring multiple devices were included
in addition to those with single defects. Finally, the
most complex procedure included was likely TPV,
which not infrequently has associated branch pul-
monary artery stenosis. TPV procedures that
included dilation and/or stenting of branch pulmo-
nary arteries were not separated from those that did
not, nor were TPV implantations during which
stenting of the right ventricular outﬂow tract wasperformed at a previous procedure separated from
those where this occurred during the same sitting.
Due to extreme heterogeneity in pathology it may be
impossible to obtain reference data for every indi-
vidual procedure type. However, barring few excep-
tions, most modiﬁable factors in radiation safety are
equipment and operator dependent. Thus, efforts
aimed at reducing radiation exposure for these 6
procedures would likely also reﬂect similar reduction
in other procedures.
CONCLUSIONS
In summary, this study represents the ﬁrst multi-
center effort to provide age-stratiﬁed radiation doses
for 6 speciﬁc interventional catheterizations in CHD.
It demonstrated that radiation exposure varies widely
among types of interventional procedures and age
group. It showed that ﬂuoroscopy time alone is not an
adequate measure for monitoring radiation exposure.
These data will facilitate application of the ACC-
endorsed pediatric radiation dose metric, namely,
the proportion of cases receiving radiation in excess
of the 95th percentile. The C3POQI project plans to
prospectively assess collaborative-wide radiation
doses biannually to determine the impact of various
QI initiatives. Additionally, nonparticipating centers
may consider using these values as a benchmark to
compare their performance.
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